Effectiveness of biosimilar pegfilgrastim in patients with lymphoma after high-dose chemotherapy and autologous stem cell transplantation: a real-life study
oleh: Barbara Loteta, Barbara Loteta, Annalisa Pitino, Martina Pitea, Martina Pitea, Caterina Alati, Caterina Alati, Giovanni Tripepi, Maria Caterina Mico', Maria Caterina Mico', Maria Pellicano', Francesca Cogliandro, Francesca Cogliandro, Gaetana Porto, Gaetana Porto, Giorgia Policastro, Giorgia Policastro, Giovanna Utano, Giovanna Utano, Ilaria Maria Delfino, Ilaria Maria Delfino, Annalisa Sgarlata, Annalisa Sgarlata, Anna Scopelliti, Anna Scopelliti, Aurora Idato, Aurora Idato, Giovanni Laenza, Maria Altomonte, Graziella D'Arrigo, Mercedes Gori, Massimo Martino, Massimo Martino
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2024-07-01 |
Deskripsi
ObjectivesTo evaluate the efficacy of biosimilar (BIO) pegfilgrastim (PEG) in lymphoma patients after autologous stem cell transplantation (ASCT).Methods86 consecutive lymphoma patients who received BIO/PEG after ASCT were assessed. The primary endpoints of this study were the incidence of febrile neutropenia (FN) and time to neutrophil engraftment.ResultsMost patients were males (67.4%) with a median age of 48 years. FN occurred in 66 patients (76.7%), and most of the fever was grade 1-2. The median time to neutrophil engraftment was 9 days. The incidence of FN differs based on lymphoma type (p-value <0.01) and was higher in non-Hodgkin lymphoma (NHL) than in Hodgkin Lymphoma (HL). No statistical difference was found between NHL and HL regarding the time to reach the neutrophil engraftment. Hospitalization lasted from a minimum of 9 to a maximum of 34 days. The restricted mean time to discharge was 15.9 days (95%CI 14-16), without differences based on lymphoma type.ConclusionAlthough the study has the significant limitation of not being randomized and not having a control arm, it highlights the efficacy and safety of a BIO-PEG formulation in patients with Lymphoma and undergoing ASCT.